Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Date:8/28/2009

approval."

Outline of the EXAMINE Trial

    Title:             A Multicenter, Randomized, Double-Blind, Placebo-
                       Controlled Study to Evaluate Cardiovascular Outcomes
                       Following Treatment with Alogliptin in Addition to
                       Standard of Care in Subjects with Type 2 Diabetes and
                       Acute Coronary Syndrome

    Study Start:       September 2009

    Study Completion:  December 2014

    No. of Patients:   Approximately 5,400

    Primary Outcome:   Time from randomization to the occurrence of the
                       Primary Major Adverse Cardiac Events defined as
                       a composite of cardiovascular death, nonfatal
                       myocardial infarction and nonfatal stroke

    Secondary Outcome: Time from randomization to the occurrence of the
                       Secondary Major Adverse Cardiac Events defined
                       as a composite of cardiovascular death, nonfatal
                       myocardial infarction, nonfatal stroke and urgent
                       revascularization due to unstable angina

    Study Sites:       Approximately 1,000 sites in the U.S., Europe, Asia

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Globa
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Fifty groups representing 500,000 patients, doctors, ... to launch the AllTrials campaign in the US. The ... and future, to be registered and the results from ... Ben Goldacre explains: "Patients want the treatments that ... on what works. Unfortunately, we now know that around ...
(Date:7/29/2015)... SAN FRANCISCO, Calif. , July 29, 2015 /PRNewswire/ ... monoclonal antibody company focused on developing innovative therapies to ... a focus on oncology, announced today that it received ... LLC ("NASDAQ") notifying the company that it is now ... listing on the NASDAQ Global Market and is no ...
(Date:7/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hmjqff/global_wound_care ) has ... Care Markets (Twelve Country Analysis: Germany, France, Italy, ... Brazil, Australia, South Korea)" report to their ... competitive market summary. The wound care market is ... product maturity. Several of the products within the ...
Breaking Medicine Technology:Fixing Your Medicine: AllTrials Campaign Launches in US 2Fixing Your Medicine: AllTrials Campaign Launches in US 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 2KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 3KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement 4Global Wound Care Markets 2015 2
... 2011 Pacira Pharmaceuticals, Inc . (Nasdaq: ... has completed a follow-on offering of 7,000,000 shares of its ... per share. Pacira also announced that its underwriters have exercised ... shares of common stock, also at $6.50 per share. All ...
... -- China Health Resource, Inc. (OTCBB: CHRI), a producer ... robust record breaking quarterly earnings for September 2011. CHRI ... in net income, a 219% increase in revenues and ... of 2010. This translates to earnings of about $0.03 ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3
(Date:7/29/2015)... ... July 29, 2015 , ... In an effort to encourage ... of substance abuse that face today’s society, A Forever Recovery invited members of ... rehabilitation center. The facility, located in Southwest Michigan hosted a tour of the ...
(Date:7/29/2015)... ... July 29, 2015 , ... VideoLink , a ... Center, located in New York, NY, selected the ReadyCam on-site video studio to ... scientists to immediately access worldwide TV and cable news networks and participate in ...
(Date:7/29/2015)... ... 29, 2015 , ... Andrzej Klos, M.D., has been reviewed and approved as ... 38 years, is motivated each and every day by his sincere desire to help ... his many awards and accolades, which include multiple listings in many highly regarded medical ...
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... organized. , Wouldn’t it be great if everyone could be a little more organized? ...
(Date:7/29/2015)... ... July 29, 2015 , ... The report “Atherosclerosis - ... Atherosclerosis is a slow, progressive disease that may start in childhood. The report ... best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and ...
Breaking Medicine News(10 mins):Health News:MADD Victim Services Specialist Visits A Forever Recovery Rehabilitation Facility 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 2Health News:Columbia University Medical Center Installs a VideoLink ReadyCam® Video Studio on Campus; Medical Experts Able to Appear on Live TV at a Moment's Notice 3Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Get More Organized with the Core Organizer App 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... , , , , ... AUDIO: University of Michigan School of Public Health researcher Stoddard,s research shows ... more information. , , , , ... , , , , , , , ...
... Reporter , THURSDAY, June 2 (HealthDay News) -- Young ... suffer from anxiety, loneliness, low self-esteem and sadness, they ... scores, new research suggests. Children do not fall ... disruptive period before their parents divorce, the study revealed. ...
... Psychology researchers at the University of Alberta have found an ... gambling: People confronted with risky choices respond differently when they ... on the odds of winning or losing. , The ... a choice between a sure win versus a double-or-nothing win. ...
... Ga. Scientists may have a way to make ... and more effective against some cancers. The chemotherapeutic agent used ... results in kidney damage or failure in about 30 percent ... physicians can do today to protect the kidneys is advise ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... be scary, but University of Michigan researchers offer some ... fallen substantially in recent years. Much of this ... in hospitals that do a lot of them and ...
... parents get divorced generally don,t experience detrimental setbacks in the ... upwhen it comes to math and interpersonal social skills after ... study. In addition, the study, which appears in the ... that children of divorce are more likely to struggle with ...
Cached Medicine News:Health News:People who have had head injuries report more violent behavior 2Health News:People who have had head injuries report more violent behavior 3Health News:People who have had head injuries report more violent behavior 4Health News:Divorce Can Hurt Kids' Math Scores, Friendships 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 3Health News:Cause and potential treatment found for cancer drug's kidney toxicity 2Health News:High-Risk Surgeries Getting Safer: Study 2Health News:High-Risk Surgeries Getting Safer: Study 3Health News:Study: Children of divorce lag behind peers in math and social skills 2
... the only four-color, automated benchtop flow cytometry ... cell sorting. Designed specifically to support a ... offers software instrument control, auto-sample loading, and ... productivity. FACSCalibur is fully modular so it ...
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
... Ultracompact high end desktop multilaser flow cytometer ... kind of cell analysis and absolute counting. ... and two different side scatter signals in ... The new CyFlow ML instrument can perform ...
This unique system combines the analytical power of a research cytometer into a compact, truly walk away, clinical analyzer ergonomically designed to expedite sample throughput....
Medicine Products: